
Opinion|Videos|December 14, 2023
Closing Reflections on Evolving Practices for Bispecific Administration
Author(s)Brooke Peters, PharmD, BCOP
Brooke Peters, PharmD, BCOP, offers a closing reflection on the transition from inpatient to outpatient treatment of bispecific antibodies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
5































